Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Researchers from Washington University, Medical Department report recent findings in breast cancer
June 25th, 2009
According to a study from the United States, "Neoadjuvant aromatase Inhibitor therapy has been reported to improve Surgical Outcomes for postmenopausal women with clinical stage II or III hormone receptor-positive breast cancer. A multicenter phase II clinical trial was conducted to investigate the value of this approach for US surgical practice." "One hundred fifteen postmenopausal women with >2 cm, estrogen receptor (ER) or progesterone receptor (PgR)-positive breast cancer were enrolled in a trial of 16 to 24 weeks of letrozole 2.5 mg daily before operation. One hundred six patients were eligible for primary analysis, 96 underwent operations, 7 received...
Source: Women's Health Weekly (2009-06-25)
|
